1. Volume 16, Issue 13, Pages 1295-1305 (October 2015)
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial 
Prof Alan K Burnett, FMedSci, Prof Nigel H Russell, MD, Robert K Hills, DPhil, Prof David Bowen, MD, Jonathan Kell, MD, Steve Knapper, DM, Yvonne G Morgan, PhD, Jennie Lok, MSc, Angela Grech, BA, Gail Jones, MD, Prof Asim Khwaja, MD, Lone Friis, PhD, Prof Mary Frances McMullin, MD, Ann Hunter, MD, Prof Richard E Clark, MD, Prof David Grimwade, PhD 
The Lancet Oncology 
Volume 16, Issue 13, Pages (October 2015)
DOI: /S (15)00193-X
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile ATRA=all-trans retinoic acid.
The Lancet Oncology  , DOI: ( /S (15)00193-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2 Quality-of-life outcomes
(A) Global health status on the EORTC QLQ-C30 over time. Numbers at baseline are forms on which global health status was evaluable. (B) Results of all subscales of the EORTC QLQ-C30 and the HADS. Effect sizes were calculated so that in all cases a positive value represents a benefit for ATRA and arsenic trioxide treatment. ATRA=all-trans retinoic acid. EORTC=European Organisation for Research and Treatment of Cancer. HADS=Hospital Anxiety and Depression Scale.
The Lancet Oncology  , DOI: ( /S (15)00193-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3 Clinical outcomes
(A) Cumulative incidence of haematological relapse. (B) Cumulative incidence of molecular or haematological relapse. (C) Overall survival in the intention-to-treat population. (D) Overall survival in low-risk patients (white blood cell count 0–9·9 × 109 cells per L). (E) Overall survival in high-risk patients (white blood cell count ≥10 × 109 cells per L). (F) Overall survival in patients older than 60 years of age. ATRA=all-trans retinoic acid. *Two patients in the ATRA and idarubicin group (one high risk and one low risk) had no follow-up data available for survival or relapse.
The Lancet Oncology  , DOI: ( /S (15)00193-X)
Copyright © 2015 Elsevier Ltd Terms and Conditions